Azenta (AZTA) Q2 2026: Multiomics Down Mid-Single Digits, Forcing 1-Year Long-Range Plan Delay
Azenta reset its long-range plan by a year after mid-single digit declines in multiomics and continued capital equipment pushouts pressured both growth and margins. Execution gaps in North America and structural cost issues surfaced as key drags, even as recurring revenue lines like biorepository and consumables held up. The company signals a disciplined operational overhaul and leadership changes to restore trajectory, but investors face a more prolonged recovery window.
Summary
- Execution Headwinds in North America: Commercial turnover and Sanger decline exposed structural weaknesses in multiomics.
- Recurring Revenue Resilience: Biorepository and consumables offset capital equipment softness, stabilizing cash flow.
- Strategic Reset Delays Targets: Long-range plan pushed to 2029, with margin and growth ambitions unchanged.
Business Overview
Azenta is a life sciences tools and services provider, generating revenue from sample management solutions (SMS, biorepositories, automated and cryogenic storage, consumables, instruments) and multiomics (gene synthesis, next-generation sequencing, Sanger sequencing). The business model blends recurring service revenue from sample storage and consumables with capital equipment sales and project-based sequencing services. SMS and multiomics are the two core segments, with recurring revenue streams a growing share of the portfolio.
Performance Analysis
Q2 exposed a widening gap between Azenta’s recurring and capital-driven businesses. Total revenue edged up 1% reported but declined 3% organically, as capital equipment orders in SMS and North America multiomics volumes both underperformed. Biorepository solutions, representing about 40% of SMS, continued to deliver high single-digit growth, demonstrating the durability of recurring revenue streams even in a cautious funding environment. Consumables and instruments also showed modest growth, but could not compensate for double-digit declines in capital-intensive automated and cryogenic store systems.
Multiomics revenue was flat reported and down 2% organically, with North America volumes weak due to both demand softness and commercial execution gaps. Europe and Asia-Pacific posted solid results, but unfavorable mix and lower fixed cost absorption drove a 300 basis point margin decline in multiomics. Gross margin overall fell 110 basis points, compounded by quality rework costs and inventory reserves. Adjusted EBITDA margin dropped to 5.4%, reflecting both lost operating leverage and ongoing investment in growth initiatives.
- Capital Equipment Order Delays: Multiple multimillion-dollar SMS deals were pushed out, impacting near-term revenue and margin leverage.
- Structural Cost Drag in Multiomics: Underutilized lab infrastructure and Sanger volume decline created $14 million in lost leverage, with 80% attributable to multiomics.
- Operational Improvements in Consumables: On-time delivery rose from 15% to 70%, showing early wins from business system deployment.
Despite these pressures, free cash flow improved to $5 million, and the balance sheet remains strong with $565 million in cash and no debt, providing flexibility for ongoing transformation and M&A.
Executive Commentary
"Candidly, we are not satisfied with our second quarter results. Overall, second quarter organic revenue was down 3% and adjusted EBITDA margin of 5.4% did not meet our expectations. While our teams remain disciplined and are delivering progress in key areas, there have been execution-related shortfalls within our control, and we are addressing them with urgency."
John Murata, President and Chief Executive Officer
"As part of our annual goodwill impairment assessment, we recorded non-cash impairment charges of $112.4 million for multi-omics and $36.6 million for sample management solutions... driven by a combination of factors, including the sustained decline in our stock price, the decrease in our near-term outlook, and a more uncertain macroeconomic and geopolitical environment."
Lawrence Lin, Executive Vice President and Chief Financial Officer
Strategic Positioning
1. North America Multiomics Reset
The underperformance in North America multiomics is largely company-specific, stemming from commercial turnover, Sanger sequencing decline, and insufficient execution. Leadership acknowledged that 60-70% of the headwinds are internal, prompting a human capital reboot and the hiring of Trey Martin to spearhead a comprehensive transformation, including a technology upgrade and footprint rationalization.
2. Recurring Revenue as a Stabilizer
Biorepository and consumables businesses are proving resilient, anchoring cash flow and margin stability even as capital equipment and project-based work remain volatile. Management is doubling down on these segments, citing strong secular drivers in ultra-cold storage and sample volume growth.
3. Modularization and Quality Overhaul in SMS
SMS is shifting from highly customized to modular, configurable store systems, aiming to improve product reliability and reduce quality issues. Engineering has been reorganized into focused teams, and the number of unresolved field quality tickets has dropped sharply, suggesting operational discipline is taking hold.
4. Margin Recovery Hinges on Cost Actions
Structural cost reductions are underway, with partial restructuring yielding $7 million in annualized savings. Further lab consolidations and right-sizing are planned, especially as Sanger volumes erode and technology shifts to next-gen sequencing and Oxford Nanopore platforms.
5. Capital Allocation and Inorganic Expansion
Azenta maintains a disciplined capital allocation framework: investing in productivity, R&D, and M&A, with share repurchases on hold pending visibility. The UK BioCenter acquisition is integrating on track, expanding European presence, while the B-Medical divestiture remains delayed due to counterparty financing.
Key Considerations
This quarter marked a strategic inflection, with management prioritizing operational rigor and segment focus as the path to restoring growth and profitability. The delay of the long-range plan (LRP) to 2029 signals a more methodical approach, but also underscores the magnitude of internal and external challenges.
Key Considerations:
- Commercial Execution Remediation: New leadership and hiring in North America multiomics will take 6-9 months to ramp, delaying a full recovery.
- Recurring Revenue Expansion: Biorepository and consumables are now the foundation for more predictable cash flow and margin resilience.
- Technology and Product Mix Shift: Sanger sequencing is in secular decline, and success depends on rapid adoption of next-gen and modular solutions.
- Cost Structure Realignment: Lab consolidations and modularization are essential to restore lost operating leverage as volumes fluctuate.
- Capital Deployment Flexibility: Cash-rich balance sheet supports transformation and selective M&A, but capital returns are secondary until execution stabilizes.
Risks
Azenta faces a dual risk profile: execution risk in North America multiomics, where commercial and structural fixes are still underway, and ongoing capital equipment order volatility, subject to macro and customer funding cycles. The delay in the B-Medical divestiture and a large non-cash impairment also highlight valuation and portfolio management risks. If cost actions or technology transitions falter, margin recovery could stall further.
Forward Outlook
For Q3 2026, Azenta expects:
- Organic revenue to grow low single digits sequentially
- Adjusted EBITDA margin to move into the low double-digit range
For full-year 2026, management lowered guidance:
- Organic revenue now expected to range from down 2% to up 1%
- Adjusted EBITDA margin to be down 125 basis points to flat year-over-year
Management cited continued North America multiomics softness, capital equipment order delays, and a more conservative pipeline assessment as drivers of the reset. Second-half performance is expected to improve on cost actions and seasonal volume recovery, but the LRP is now targeted for 2029, not 2028.
- Volume recovery and cost savings are critical to margin improvement
- Execution in North America and modular SMS rollout are key watchpoints
Takeaways
Azenta’s Q2 2026 marked a tactical retreat and operational reset, as internal execution issues and capital equipment volatility forced a delay in its long-range ambitions.
- North America Multiomics Is the Core Drag: Commercial turnover and Sanger decline are company-specific and must be fixed internally before growth can recover.
- Recurring Revenue Shields Volatility: Biorepository and consumables are the ballast for the business and the primary source of resilience.
- Transformation Will Take Time: Investors should expect a gradual improvement as new leadership, cost actions, and modularization play out over several quarters.
Conclusion
Azenta’s operational reset and LRP delay reflect the reality of persistent execution gaps and market caution. While recurring revenue lines remain robust, the path to margin and growth recovery depends on North America multiomics stabilization and successful cost realignment. Investors should monitor progress on these fronts as the company navigates a more protracted turnaround.
Industry Read-Through
Azenta’s results highlight the fragility of capital-driven life science tools businesses in a cautious funding environment, especially for those with execution gaps or legacy cost structures. The resilience of recurring revenue models—biorepository, consumables, and service contracts—will be increasingly prized as academic and biotech funding cycles remain unpredictable. Secular shifts in sequencing technology (Sanger to next-gen and Oxford Nanopore) are accelerating, pressuring legacy platforms and requiring rapid adaptation. Competitors with modular, scalable solutions and disciplined operational execution are likely to gain share as customers demand reliability and cost efficiency. The delayed LRP and impairment at Azenta also serve as a warning for peers: transformation is slow and costly if not matched by execution speed and market alignment.